FDA Moves to End Self-Affirmed GRAS, Mandatory Notification Coming for New Ingredients
The FDA is preparing to propose a significant change to how food and supplement ingredients enter the U.S. market. The proposed rule, expected to land on the agency’s regulatory agenda in spring or summer 2026, would close the door on a practice that has gone largely unchecked for nearly three decades: companies self-certifying that an ingredient is safe without ever telling the FDA.
What GRAS Actually Means
GRAS is short for Generally Recognized As Safe. When Congress amended the Federal Food, Drug, and Cosmetic Act in 1958, the intent was practical. Ingredients like salt, vinegar, and baking soda, with centuries of safe use behind them, should not require the same formal approval process as novel food additives. If scientific consensus already supported an ingredient’s safety, a separate FDA review felt redundant.
That logic made sense in 1958. The landscape shifted in 1997 when the FDA introduced a voluntary notification program and, alongside it, acknowledged that companies could skip notification entirely. As long as a company had its own experts confirm safety, it could market the ingredient as GRAS with no agency review at all. This became known as the self-affirmed GRAS pathway.
The consequence: thousands of ingredients currently on shelves have never been reviewed by the FDA. The agency has little visibility into what is entering the food supply.
Kennedy’s Direction and What the Rule Would Require
HHS Secretary Robert F. Kennedy Jr. directed the FDA to explore closing this gap. The proposed rule would require companies to notify the FDA and submit supporting safety data before marketing any new ingredient. The ingredient could not go to market until the FDA had completed its review.
This would effectively make the voluntary notification system mandatory and eliminate the self-affirmed pathway entirely.
What Stays Untouched
Existing protections are not being rewound. Ingredients already listed on the official GRAS registry and those that previously received no-questions letters from the FDA are grandfathered in. Astaxanthin, the carotenoid pigment recognized for its antioxidant properties, received GRAS status in early 2026 and falls within this protected group.
For most supplement users, products currently on shelves are unlikely to be disrupted. The vast majority of established ingredients have already cleared some form of regulatory review.
The Supplement Angle
Supplements operate under a parallel system called NDI, or New Dietary Ingredient notification. Any dietary ingredient introduced to the market after October 15, 1994 requires pre-market notification to the FDA under the Dietary Supplement Health and Education Act.
If the GRAS reform takes effect, novel ingredients that cross food and supplement categories could find themselves navigating both notification systems. Industry groups have raised concerns about processing timelines. If notification volumes surge after the rule takes effect, review backlogs could slow the launch of new ingredients significantly.
The NMN situation offers a useful reference point. Nicotinamide mononucleotide, a precursor to NAD+ and a compound studied for its role in cellular energy and longevity, was blocked from the supplement market in 2022 after the FDA determined that it had been investigated as a drug first. In September 2025, the FDA reversed that decision, and NMN returned to shelves as a lawful supplement ingredient. Regulatory status is not fixed, and changes can move in either direction.
The Consumer Calculus
A higher pre-market safety bar is a concrete gain for shoppers. When ingredients can reach shelves through a pathway the FDA never sees, there is no practical safeguard against safety problems showing up only after widespread use.
The offset is speed. Ingredients backed by solid science could sit in regulatory limbo for months or years after a rule like this takes effect. The benefit arrives eventually, but the wait is real.
The proposed rule has not been finalized. A public comment period will follow, and the final language could shift based on industry and public response. The substantive debate begins when the FDA formally submits the proposal later this year.
Frequently Asked Questions
What is GRAS, and how has it worked until now? GRAS stands for Generally Recognized As Safe. It was introduced in 1958 to allow well-established ingredients with a long history of use to enter the food supply without formal approval. The problem started in 1997, when the FDA permitted companies to self-affirm an ingredient as GRAS and bring it to market without ever notifying the agency. Today, thousands of ingredients are circulating in food and supplements without any FDA review.
Will products currently on the market be affected? No, ingredients already on the official GRAS list or those that received a no-questions letter from the FDA are exempt. The change targets new ingredients going forward. For supplements specifically, the separate NDI (New Dietary Ingredient) notification process also applies, meaning new ingredients may effectively need to clear two regulatory pathways.
Why does this matter for consumers? A mandatory pre-market safety review means fewer ingredients reach shelves without independent scrutiny. The trade-off is that new ingredients with strong research behind them could face longer waits before becoming available. The NMN story, where the FDA reversed its exclusion in September 2025 and reinstated it as a lawful supplement ingredient, shows how quickly the regulatory ground can shift. Staying informed about the status of newer ingredients is worth the effort.